NONPRICE DRUG DIFFERENCES SHOULD BE CONSIDERED BY HCFA IN REIMBURSEMENT REFORM TO AVOID CHILL ON DEVELOPMENT OF THERAPEUTICALLY EQUIVALENT PRODUCTS, FTC SAYS